arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Relay Therapeutics, Inc.

RLAY
$18.02 ▼ -1.35 (-6.97%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
31 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Relay Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.7B
Dividend Yield
Revenue Growth -48.3%
Op. Margin None
ROIC -8.1%
FCF / Share $-0.27
Trailing P/E
Price / Book 4.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$350.00K
↓ -48.3%
Net Income Profit after all expenses
$-73.29M
↑ +4.9%
FCF / Share Free cash flow per share
$-0.27
↑ +6.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters